Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SCN1A | P35498 | 1/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.61 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 5/20 | 0.57 |
| ▸ | ACHE | P22303 | 5/20 | 0.57 |
| ▸ | EBP | Q15125 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473605 | 0.92 | MAPT (0.70) | MAPTHRH3LMNASCN1ASCN2A | |
| SCHEMBL2472562 | 0.90 | MAPT (0.66) | MAPTHRH3LMNASCN1ASCN2A | |
| SCHEMBL6268022 | 0.87 | LMNA (0.72) | MAPTHRH3LMNASCN1ASCN2A | |
| SCHEMBL4966044 | 0.84 | MAPT (0.72) | MAPTHRH3RAB9ABCHEACHE | |
| SCHEMBL491797 | 0.84 | L3MBTL1 (0.69) | HRH3LMNASCN1ASCN2ASCN3A | |
| SCHEMBL5418369 | 0.84 | TP53 (0.64) | HRH3BCHEACHEEBPSIGMAR1 | |
| SCHEMBL1795293 | 0.84 | MAPT (0.62) | MAPTRAB9ABCHEACHEMAOB | |
| SCHEMBL7937774 | 0.84 | MAPT (0.82) | MAPTRAB9ATDP1L3MBTL1 | |
| SCHEMBL2469151 | 0.84 | MAPT (0.89) | MAPTLMNARAB9ATDP1L3MBTL1 | |
| SCHEMBL492102 | 0.83 | HRH3 (0.61) | HRH3LMNASCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077455-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | MAPT 1072/4885HRH3 2660/4885LMNA 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.